Drugs / Daratumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04972942 | May 2023 → Sep 2027 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | New York Medical College | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06015724 | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04065789 | May 2018 → Aug 2021 | plasma cell myeloma | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02977494 | Jun 2016 → Jun 2021 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07072585 | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03768960 | Jun 2019 → Jul 2022 | plasma cell myeloma | Johnson & Johnson Private Limited | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07015021 | Jun 2025 → Sep 2026 overdue | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02977494 ↗ |
| Modality | Monoclonal antibody | “human IgG1monoclonal Antibody (mAb)” NCT02977494 ↗ |
| Route | Intravenous | “DARA IV weekly x 8 doses (Weeks 1-8)” NCT04972942 ↗ |
| Target | CD38 | “anti-CD38 monoclonal antibody (mAb)” NCT06015724 ↗ |